FDA puts on hold two Rapt Therapeutics mid-stage drug trials (updated)
20/02/2024 12:58
(Adds details in paragraphs 2 and 3)
Feb 20 (Reuters) - Rapt Therapeutics RAPT.O said on
Tuesday the U.S. FDA had placed on hold two mid-stage trials of
the company's drug to treat eczema and asthma, after liver
failure was observed in one of the patients.
The company said it had enrolled 350 patients across the two
mid-stage trials and a previous early-stage study of the drug,
zelnecirnon, but no evidence of liver toxicity was observed with
any other patient.
Following the hold, Rapt will halt dosing of existing
patients and stop enrollment of new participants, while it
conducts a thorough investigation of this case.
(Reporting by Leroy Leo and Puyaan Singh in Bengaluru; Editing
by Shilpi Majumdar and Devika Syamnath)
((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))